Drugs / CAR-T Cell Injection
last change Dec 2025 re-read 2 minutes ago

CAR-T Cell Injection

Cell therapy

Developed for
nasopharyngeal carcinoma
Investigated by
Guangzhou Bioresette Biomedical Technology Co., Ltd. · The Affiliated Hospital of Xuzhou Medical University

Trials 1 · a red edge is where a trial was stopped

20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 0 NCT05654077 Jan → Dec 2022 nasopharyngeal carcinoma The Affiliated Hospital of Xuzhou Medical University Unknown No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CAR-T Cell Injection ClinicalTrials.gov intervention name — accepted as the source's own label NCT05654077
Modality Cell therapy “EBV CAR-T cells” NCT05654077
Route Intravenous “single intravenous infusion of CAR-T cells” NCT05654077